Quality-Adjusted Survival in Patients with Metastatic Colorectal Cancer Treated with Fruquintinib in the FRESCO Trial

Shukui Qin(Memorial Sloan Kettering Cancer Center), Lin Shen(Peking University), Songhua Fan, Xiaojun Guo(China Banking Regulatory Commission), Cike Peng(Lilly (China)), Yuxian Bai(Harbin Medical University), Mengye Peng, Ning Wang(Shanghai Ninth People's Hospital), Yun Chen(Lilly (China)), Hongyan Li(Yantaishan Hospital), Haijun Zhong(Zhejiang Cancer Hospital), Jianming Xu(Chinese PLA General Hospital), Zhendong Chen(Anhui Medical University), Weijian Guo, Li Jin(Fudan University Shanghai Cancer Center), Rui‐Hua Xu(Sun Yat-sen University), Yongqian Shu(Jiangsu Provincial Hospital of Traditional Chinese Medicine), Yanhong Deng(Sun Yat-sen University), Lei Yang(Nantong Tumor Hospital), Hongming Pan(Sir Run Run Shaw Hospital)
Future Oncology
February 10, 2021
10.2217/fon-2020-1215
Cited by 7

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k